Stai usando un browser molto obsoleto. Puoi incorrere in problemi di visualizzazione di questo e altri siti oltre che in problemi di sicurezza. . Dovresti aggiornarlo oppure usarne uno alternativo, moderno e sicuro.
NEW YORK (Dow Jones)--Shares of PSivida Corp. (PSDV) jumped as much as 15% Monday as investors eagerly awaited data from a Phase III trial of Iluvien.
The company has said in the past that it expects to report safety and efficacy data from the trial by the end of December for the drug treating diabetic macular edema, a potentially blinding eye disease affecting over 1 million people in the U.S. There currently are no drugs approved ...